These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 38358343)

  • 61. Impact of proprotein convertase subtilisin/kexin type 9 inhibition with evolocumab on the postprandial responses of triglyceride-rich lipoproteins in type II diabetic subjects.
    Taskinen MR; Björnson E; Andersson L; Kahri J; Porthan K; Matikainen N; Söderlund S; Pietiläinen K; Hakkarainen A; Lundbom N; Nilsson R; Ståhlman M; Adiels M; Parini P; Packard C; Borén J
    J Clin Lipidol; 2020; 14(1):77-87. PubMed ID: 31917184
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Liraglutide downregulates hepatic LDL receptor and PCSK9 expression in HepG2 cells and db/db mice through a HNF-1a dependent mechanism.
    Yang SH; Xu RX; Cui CJ; Wang Y; Du Y; Chen ZG; Yao YH; Ma CY; Zhu CG; Guo YL; Wu NQ; Sun J; Chen BX; Li JJ
    Cardiovasc Diabetol; 2018 Apr; 17(1):48. PubMed ID: 29618348
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Proprotein Convertase Subtilisin/Kexin-Type 9 and Lipid Metabolism.
    Guo S; Xia XD; Gu HM; Zhang DW
    Adv Exp Med Biol; 2020; 1276():137-156. PubMed ID: 32705598
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Inhibition of monoamine oxidase B reduces atherosclerosis and fatty liver in mice.
    Wang SH; Tsai FC; Lin HH; Yu TY; Kuo CH; Li HY; Lin MS
    Clin Sci (Lond); 2023 Jan; 137(1):17-30. PubMed ID: 36416117
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Differential cholesterol uptake in liver cells: A role for PCSK9.
    Luquero A; Vilahur G; Casani L; Badimon L; Borrell-Pages M
    FASEB J; 2022 May; 36(5):e22291. PubMed ID: 35344222
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Proprotein convertase subtilisin/kexin 9 inhibitors: an emerging lipid-lowering therapy?
    Dragan S; Serban MC; Banach M
    J Cardiovasc Pharmacol Ther; 2015 Mar; 20(2):157-68. PubMed ID: 24938457
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Anacetrapib reduces (V)LDL cholesterol by inhibition of CETP activity and reduction of plasma PCSK9.
    van der Tuin SJ; Kühnast S; Berbée JF; Verschuren L; Pieterman EJ; Havekes LM; van der Hoorn JW; Rensen PC; Jukema JW; Princen HM; Willems van Dijk K; Wang Y
    J Lipid Res; 2015 Nov; 56(11):2085-93. PubMed ID: 26342106
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Sirtuin 6-A Key Regulator of Hepatic Lipid Metabolism and Liver Health.
    Dong XC
    Cells; 2023 Feb; 12(4):. PubMed ID: 36831330
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Non-Native Conformational Isomers of the Catalytic Domain of PCSK9 Induce an Immune Response, Reduce Lipids and Increase LDL Receptor Levels.
    Jiang C; Nischal H; Sun H; Li L; Cao Y; Wei P; Chang JY; Teng BB
    Int J Mol Sci; 2018 Feb; 19(2):. PubMed ID: 29495280
    [TBL] [Abstract][Full Text] [Related]  

  • 70. New CETP inhibitor K-312 reduces PCSK9 expression: a potential effect on LDL cholesterol metabolism.
    Miyosawa K; Watanabe Y; Murakami K; Murakami T; Shibata H; Iwashita M; Yamazaki H; Yamazaki K; Ohgiya T; Shibuya K; Mizuno K; Tanabe S; Singh SA; Aikawa M
    Am J Physiol Endocrinol Metab; 2015 Jul; 309(2):E177-90. PubMed ID: 26015437
    [TBL] [Abstract][Full Text] [Related]  

  • 71. An anti-PCSK9 antibody reduces LDL-cholesterol on top of a statin and suppresses hepatocyte SREBP-regulated genes.
    Zhang L; McCabe T; Condra JH; Ni YG; Peterson LB; Wang W; Strack AM; Wang F; Pandit S; Hammond H; Wood D; Lewis D; Rosa R; Mendoza V; Cumiskey AM; Johns DG; Hansen BC; Shen X; Geoghagen N; Jensen K; Zhu L; Wietecha K; Wisniewski D; Huang L; Zhao JZ; Ernst R; Hampton R; Haytko P; Ansbro F; Chilewski S; Chin J; Mitnaul LJ; Pellacani A; Sparrow CP; An Z; Strohl W; Hubbard B; Plump AS; Blom D; Sitlani A
    Int J Biol Sci; 2012; 8(3):310-27. PubMed ID: 22355267
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Intravascular hemolysis triggers NAFLD characterized by a deregulation of lipid metabolism and lipophagy blockade.
    Rayego-Mateos S; Morgado-Pascual JL; García-Caballero C; Lazaro I; Sala-Vila A; Opazo-Rios L; Mas-Fontao S; Egido J; Ruiz-Ortega M; Moreno JA
    J Pathol; 2023 Oct; 261(2):169-183. PubMed ID: 37555366
    [TBL] [Abstract][Full Text] [Related]  

  • 73. ABO blood group in relation to plasma lipids and proprotein convertase subtilisin/kexin type 9.
    Li S; Xu RX; Guo YL; Zhang Y; Zhu CG; Sun J; Li JJ
    Nutr Metab Cardiovasc Dis; 2015 Apr; 25(4):411-7. PubMed ID: 25466598
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Serum proprotein convertase subtilisin/kexin type 9 and cell surface low-density lipoprotein receptor: evidence for a reciprocal regulation.
    Tavori H; Fan D; Blakemore JL; Yancey PG; Ding L; Linton MF; Fazio S
    Circulation; 2013 Jun; 127(24):2403-13. PubMed ID: 23690465
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Olanzapine-induced nonalcoholic fatty liver disease: The effects of differential food pattern and the involvement of PGRMC1 signaling.
    Zhu Z; Cao T; Chen H; Zhang B; Lin C; Cai H
    Food Chem Toxicol; 2023 Jun; 176():113757. PubMed ID: 37019375
    [TBL] [Abstract][Full Text] [Related]  

  • 76. PCSK9 Biology and Its Role in Atherothrombosis.
    Barale C; Melchionda E; Morotti A; Russo I
    Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34070931
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Peroxisome proliferator-activated receptor α activation induces hepatic steatosis, suggesting an adverse effect.
    Yan F; Wang Q; Xu C; Cao M; Zhou X; Wang T; Yu C; Jing F; Chen W; Gao L; Zhao J
    PLoS One; 2014; 9(6):e99245. PubMed ID: 24926685
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Effects of antiretroviral therapy on proprotein convertase subtilisin/kexin 9: focus on lipids, inflammation and immunovirological parameters.
    Bianconi V; Schiaroli E; Pirro M; Cardaci S; Busti C; Mannarino MR; Baldelli F; Francisci D
    HIV Med; 2020 Sep; 21(8):512-522. PubMed ID: 32496664
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Inhibition of PCSK9 prevents and alleviates cholesterol gallstones through PPARα-mediated CYP7A1 activation.
    Chen Z; Shao W; Li Y; Zhang X; Geng Y; Ma X; Tao B; Ma Y; Yi C; Zhang B; Zhang R; Lin J; Chen J
    Metabolism; 2024 Mar; 152():155774. PubMed ID: 38191052
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: Present perspectives and future horizons.
    Yadav K; Sharma M; Ferdinand KC
    Nutr Metab Cardiovasc Dis; 2016 Oct; 26(10):853-62. PubMed ID: 27352986
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.